• Docetaxel: From Microtubules to Translation

  2026-08-13

  Docetaxel, also known as Taxotere, is more than a cytotoxic benchmark: it is a mechanistic probe for connecting microtubule dynamics, mitotic failure, apoptosis, resistance biology, and translational study design. This thought-leadership guide shows how to use Docetaxel strategically in cancer chemotherapy research while integrating exposure control, model selection, and supportive-care considerations.

• Toremifene Citrate: From SERM to Strategy

  2026-08-13

  A translational framework for using Toremifene Citrate to connect estrogen receptor biology, breast cancer models, exposure design, and clinically relevant decision-making.

• Caspase-8 Fluorometric Assay Kit Workflow

  2026-08-12

  Translate treatment-induced cell death into a quantitative Caspase-8 activity readout with an IETD-AFC fluorescence workflow. This guide connects combination-therapy experiments, apoptosis profiling, and troubleshooting with practical controls and interpretation limits.

• AG-221 (Enasidenib) in IDH2-Mutant AML

  2026-08-12

  AG-221, also called Enasidenib, selectively inhibits mutant IDH2 and suppresses the oncometabolite 2-hydroxyglutarate. It is a research tool for acute myeloid leukemia models, while clinical use is limited to defined IDH2-mutated AML settings.

• Sunitinib and Ferroptosis in Renal Cancer Research

  2026-08-11

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor whose activity extends beyond angiogenic signaling. This article explains how TRIB3/SLC7A11/GPX4 biology can guide ferroptosis-focused assays and studies of renal cell carcinoma drug sensitivity.

• 3-Hydroxybutyrate (BHBA) in Ferroptosis Assays

  2026-08-11

  Use 3-hydroxybutyrate (BHBA) as a defined ketone-body perturbation to model metabolic stress, ferroptosis resistance, and chromatin responses in cell systems. This workflow translates stroke neuroprotection findings into practical dose-finding, oxygen-glucose deprivation/reoxygenation, and mechanism-validation experiments.

• ML216: BLM Helicase Inhibitor Research Guide

  2026-08-10

  ML216 is a BLM helicase inhibitor with submicromolar-to-low-micromolar biochemical potency and reported selectivity over selected related helicases. Its research value spans BLM-dependent DNA repair studies, sister chromatid exchange analysis, cell proliferation inhibition assays, and preclinical cancer models, but it should not be treated as a clinically validated or WRN-selective agent.

• Colistin–Gamithromycin Synergy in P. multocida

  2026-08-09

  Li and colleagues combined susceptibility testing, time-kill analysis, pharmacokinetics, and a neutropenic murine pneumonia model to examine colistin–gamithromycin therapy against Pasteurella multocida. The study shows that synergy was strongest in high-colistin-MIC isolates and that pharmacodynamic exposure targets could support substantially lower gamithromycin dosing than monotherapy, while also emphasizing that combination effects were isolate dependent.

• Streptavidin-Cy3 for NPC Metastasis Research

  2026-08-08

  Streptavidin-Cy3 converts biotinylated antibodies and nucleic-acid probes into a bright spatial readout for NPC metastasis studies. This guide connects the seRNA-NPCm/NDRG1 mechanism with practical IHC, ISH, immunofluorescence, and flow cytometry workflows, including optimization and troubleshooting strategies.

• Dual-Network Hydrogel Microspheres for IVDD

  2026-08-07

  The reference study develops an elastic, stimulus-responsive microsphere platform that combines inflammation modulation with miR-155 delivery to protect nucleus pulposus cells during intervertebral disc degeneration. Its significance lies in integrating mechanical stability, oxidative-environment responsiveness, intracellular antioxidant activity, and apoptosis regulation within one biomaterial system.

• AICAR Phosphate (Acadesine): Reliable AMPK Activation for Ap

  2026-08-07

  This article provides a scenario-driven, evidence-based exploration of AICAR phosphate (Acadesine, SKU B1211) as a robust tool for apoptosis and cell viability assays. Addressing key laboratory challenges in reproducibility and sensitivity, it integrates recent mechanistic insights and practical workflow guidance. Researchers gain actionable strategies and direct links to performance data for SKU B1211.

• Epalrestat and Aldose Reductase Inhibition: New Frontiers in

  2026-08-06

  Explore how Epalrestat, a potent aldose reductase inhibitor, is reshaping research into cancer metabolism and neurodegenerative disease through advanced polyol pathway targeting. This in-depth analysis delivers practical insights and novel applications beyond traditional diabetic neuropathy models.

• UVB-Induced Mutation Signatures in Keratinocytes via Exome S

  2026-08-06

  This study leveraged whole exome sequencing to reveal new mutation patterns and driver mutation hotspots induced by UVB irradiation in human keratinocytes. It also demonstrated how chromatin state, modulated by trichostatin A, significantly influences UVB mutagenesis, with implications for skin cancer research and DNA damage assessment.

• Ouabain in Senolytic and Cardiovascular Research: Mechanisms

  2026-08-05

  Explore how Ouabain, a selective Na+/K+-ATPase inhibitor, advances both senolytic discovery and cardiovascular research. This in-depth article uniquely bridges molecular mechanism, AI-driven assay evolution, and practical guidance for researchers.

• Epalrestat: Redefining Neuroprotection in Translational Rese

  2026-08-05

  This thought-leadership article synthesizes mechanistic insights and strategic guidance for translational researchers using Epalrestat, a potent aldose reductase inhibitor. Drawing on new evidence for KEAP1/Nrf2 pathway activation in Parkinson's disease, it explores experimental validation, protocol optimization, and the competitive landscape—advancing the conversation beyond routine product descriptions.

16298 records 1/1087 page Next 12345 下5页 Last page